IL17A and intestinal cancer: Specifically, IL-17A mediates the progression of intestinal cancer in mouse models49 acting on transformed enterocytes50 and with IL-6 and tumor necrosis factor-alpha (TNF)-promoting CRC cell growth via signal transducer and activator of transcription 3 (STAT3) and nuclear factor-kappa-B (NFκB) activation51.